Leronlimab (350 mg) Weekly Use for 14 Weeks in Open Label Arm of NASH Trial Produces Fibrosis Reduction as High as 93 Msec amongst First 15 Patients with Average Reduction of 24 Msec

CytoDyn Inc., a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, reported data from its trial treating nonalcoholic steatohepatitis (NASH) open label with leronlimab.